Latest Updates
Tampilkan postingan dengan label medication. Tampilkan semua postingan
Tampilkan postingan dengan label medication. Tampilkan semua postingan

No man's land


Elizabeth Aquino (left) is a Los Angeles writer and a fierce advocate for her daughter Sophie (right), who she writes about on her blog: A moon, worn as if it had been a shell. In this essay, she recalls the moment when she recognized that neurologists and science had no practical answers for treating her baby’s severe seizures. At the time, she lived in New York. The essay appeared in the Dec. 2008 online issue of Exceptional Parent Magazine. Thank you Elizabeth!

No man’s land
By Elizabeth Aquino

Fourteen years ago, when my daughter Sophie was diagnosed with a severe seizure disorder of unknown origin, I didn’t own a computer. When the doctor explained what was wrong with Sophie, I listened carefully but didn’t even take notes. I’m a smart, organized person and I trusted that she would tell me everything I needed to know.

“You shouldn’t really read anything about infantile spasms,” she advised. “It’s all very depressing.”

One day after leaving the hospital, I made my way to the Barnes and Noble on Broadway and 84th Street. It was a spectacularly new and huge bookstore and had already squeezed out the more intimate and beloved independent booksellers in my neighbourhood. But the immensity of the store, coupled with the bright lights and gleaming escalators, were reassuring. Surely I would find some answers in these slick stacks of newness.

I made my way to the children’s health section and promptly fell upon a book entitled “Seizures and Epilepsy in Childhood” by Dr. John Freeman. I flipped to the index and read “infantile spasms, page 108.” I turned to page 108 and crouched down on the gray carpeting to read.

“Only 10 to 20 percent of children with infantile spasms will have normal mental function; the vast majority will have moderate to severe mental retardation. This is the only (emphasis theirs) seizure type where one can predict such a poor outlook.”

I reread the lines, this time with my finger tracing the words. My lips moved, repeating the sentences over and over. A woman excused herself and reached around me for a book about colic. On the other side of the bookshelf, toddlers raced around their strollers and nannies, city babies at play. I swallowed and continued reading, the letters black and pulsating, a perverse seduction. This was knowledge.

About six months later, Sophie has already been on six drugs. Her seizures continue unabated and her development has plateaued. She’s nine-months-old and spends most of her day moaning. A new doctor assures us it’s plain irritability. A “side effect,” he says, “that you’ll have to figure out your tolerance for.” He recommends a new drug not yet approved by the FDA but available by fax through a pharmacy in London.

“Wow,” I think, “Europeans are always so much more sophisticated. We’ll try it.”

He writes us a prescription and gives us the fax number for the pharmacy in London. I imagine a small place on a cobble-stoned street, where the pharmacist still mixes drugs. I’m in Atlanta with Sophie, visiting my parents for the Christmas holidays.

The London pharmacy sends me the drug in individual foil packets. Each packet is a single dose, but for an adult. I have to gently shake the contents onto the counter and split it in half with a knife. It doesn’t seem so accurate, so I use a credit card, wielding it like the cocaine users I watched in college. The amount I give her could fit in a quarter teaspoon, fine white granules that appear smaller than sugar or salt. I lick my finger and place it in the powder and then gingerly on my tongue. It’s incredibly bitter so I spit it out. I have never been a drug user so am fascinated that such a minuscule amount can actually stop seizures. We add the drug to Sophie’s other two, a cocktail of the non-FDA-approved. And then we wait to see if it’ll work.

On the third night, Sophie doesn’t sleep. Screaming, she flails her hands and arches her back. She’s a wreck. It goes on all night for several nights. Sometimes, she quiets unexpectedly and collapses, exhausted, in her crib. I go downstairs and walk into the dimly lit living room where my mother sits, shadowed, in an armchair. She has insomnia. I kneel down next to her, lay my head in her lap and weep. She brushes the hair back from my face and says nothing.

When the wailing begins again, I climb the stairs and go to Sophie. I pick her up and walk with her, clutched to my chest but unable to cry anymore. I whisper into her ear and to the air around us, “Enough. This is enough. We will stop this.”

The next morning, I call the neurologist back in New York. I tell him that Sophie has been acting psychotic (if a baby can act psychotic). I tell him that her seizures have not shown any improvement, that she screams for most of the night, and that she appears very uncomfortable. The neurologist says little.

“Do you think that maybe the two drugs that are not FDA-approved are interacting with each other?” I say. “I mean, how many babies do you know on that particular combination?”

There’s silence. I picture the neurologist with his hand on his chin, stroking it like my third-grade math teacher Mrs. St. Andre did when she was thinking.

“Hmmm,” he says, “that’s a very interesting idea.”

For a second, I can’t breathe. His voice has travelled two thousand miles into my ear but his words are black blocks in a cartoon bubble in front of me.

I think, Shit. I have a good idea. I have a bachelor’s degree in English and French literature and he’s a neurologist, but I have a good idea. Shit. We are in no man’s land.

That moment I realized with stunning clarity that we were on our own in the care of our daughter and that no amount of scientific knowledge or experience would serve as comfort. In the space of a sentence, I felt I was shoulder to shoulder with the great minds of neurology. It felt like a crap shoot, and the only power I had was to stop.

I stopped that drug and began weaning it from Sophie’s body that day. I began to look and listen for alternatives and eventually found my way to an osteopath in southern California who worked primarily with brain-injured children. We would continue to work with neurologists over the years, open to new drugs and willing to try treatments, but I would never regain a sense of trust that the land we were traversing was known to anyone.

Today, when I get on my computer and 'google' any term I want, I am far from the frightened reader in the Barnes and Noble on Broadway. The words are plucked from some no man’s land and assemble themselves on the screen in front of me. For a while I pretend that I have a bit more knowledge than before and that it’s so accessible, right at my fingertips.

On the trail of an autism treatment



I was interested to learn that Dr. Evdokia Anagnostou (above) – a child neurologist at Bloorview developing a clinical research program in autism – was one of the authors of the new study showing that the antidepressant Celexa doesn’t work for repetitive behaviours in children with autism.

Celexa is one of the newer drugs in the selective serotonin-reuptake inhibitor (SSRI) class of antidepressants – which are the most commonly prescribed drugs for children with autism.

The results that showed Celexa is not useful in treating repetitive behaviours in children with autism were a surprise even to the authors of the Archives of General Psychiatry study, which was published this month.

“We couldn’t believe our eyes,” says Evdokia, who was working at the time at the Mount Sinai School of Medicine. “We all have this ‘gestalt’ that this drug is effective at decreasing repetitive behaviours, but the truth is that it doesn’t work better than placebo."

In the American study, 149 children with autism aged five to 17 received either Celexa or a placebo over three months.

Researchers wanted to know if Celexa reduced behaviours that can interfere with a child’s ability to learn – like compulsions, restricted interests and hand flapping.

The study found that about one out of three children in both the Celexa and control groups showed fewer or less severe repetitive behaviours, but there was no significant difference in improvement between the groups. And Celexa was significantly more likely to cause impulsiveness, inattention and sleep problems.

The study was the largest randomized trial of a medication to treat autism.

Evdokia was recruited to Bloorview last year and part of her autism research focuses on testing alternative compounds like fish oil.

“There’s a new movement within the research community to look at alternative compounds in a scientific way,” Evdokia says. “Parents and physicians have started using these compounds without any evidence that they’re safe or effective. We want to test them scientifically.”

This fall, she’s conducting a randomized control trial to study the impact of omega-3 fatty acids on preschoolers with autism.

Thirty-five preschoolers will receive fish oil and 35 will receive a placebo over six months. “We want to see if the omega-3 fatty acids have an impact on the core symptoms of autism – social communication deficits and repetitive behaviours – and on associated symptoms like aggression and anxiety.” Because fish oil has an excellent safety profile, “we can target the very young, where usually we are uncomfortable prescribing traditional medications.” There’s some evidence to show that fish oil can benefit children with neurodevelopmental disabilities, but the compound hasn’t been tested using statistical methods, Evdokia says.

In the meantime, if you're a parent of a child with autism taking Celexa, ask your doctor what symptoms it was intended to treat. "We found it’s not useful for treating repetitive behaviours, but Celexa is also used for anxiety, and we didn't test anxiety in this study," Evdokia notes.

Evdokia says cognitive-behavioural therapy can be helpful in reducing repetitive behaviours, but it's not covered by Ontario hospital insurance and is expensive. And there are few pediatric psychologists with experience treating this population.

Do you have a child whose treatment was affected by the findings on Celexa?